PIM1 and plasma cell myeloma: In addition to the synergy of PIM447 with standard anti-myeloma agents reported by our group [6], other synergistic combinations of PIM inhibitors with either classical chemotherapeutic or novel agents have been reported in preclinical models of several hematologic diseases [10,11,12], including MM [7,8,13].